Hypnotic Drugs RUSSELL R

Total Page:16

File Type:pdf, Size:1020Kb

Hypnotic Drugs RUSSELL R Postgrad Med J: first published as 10.1136/pgmj.46.535.314 on 1 May 1970. Downloaded from Pcstgraduate Medical Journal (May 1970) 46, 314-317. CURRENT SURVEY Hypnotic drugs RUSSELL R. MILLER* DIRK V. DEYOUNG Pharm. D. M.D. Director, Drug Communications Study, Assistant Medical Director, University of Chicago Continental Assurance Company, Chicago JAMES PAXINOS B.S (Pharm.) Assistant Director for Clinical Services, Department ofPharmacy, University of Chicago Hospitals and Clinics THIS review will treat the more commonly prescribed Human pharmacology hypnotic agents and their sleep-inducing properties. In the past, hypnotics have been divided into Hypnotic agents that are seldom used (paraldehyde), barbiturates and non-barbiturates. This classification, drugs that are not singularly soporific but may be based on chemical structure, has little contemporary used either alone or as adjuncts in inducing sleep [e.g. clinical significance since compounds in each group meprobamate (Equanil, Miltown), chlordiazepoxide have essentially the same qualitative pharmacologic (Librium) and diazepam (Valium)] and drugs that properties. Naturally, there are quantitative differ- copyright. have little soporific effect [antihistamines, bromides ences in onset and duration of action. and methylparafynol (Oblivon, Dormison) (Lasagna, 1954)] will not be discussed. Onset of action Indications Onset is generally rapid with liquid preparations Insomnia is an extremely common complaint with such as syrup of chloral hydrate (Noctec, Somnos), which are confronted. elixir of pentobarbital (Nembutal) and elixir of physicians perpetually Many not as patients have chronic insomnia. In other patients secobarbital (Seconal). However, liquids are http://pmj.bmj.com/ insomnia is acute but intermittent. Situations in convenient as capsules and since a capsule of sodium which acute insomnia can occur are during or after secobarbital, sodium pentobarbital or chloral plane or train travel, hospitalization in strange and hydrate usually causes drowsiness within about often noisy surroundings or simply having to sleep 30 min, these three compounds give quite satis- in environments that are different or unfamiliar. factory hypnotic results in most patients in capsular There appear to be three basic types of insomnia. form. In one a has in Onset of action is also related to the intrinsic type person difficulty only falling on September 29, 2021 by guest. Protected asleep. In a second type, individuals achieve sleep pharmacodynamic nature of the particular hypnotic easily, but have trouble staying asleep. In a third agent. An 'ultra-short acting' barbiturate such as type, both falling and remaining asleep are physiolo- hexobarbital (Sombulex, Cyclonal) probably has the gically arduous. most prompt onset of action while a 'long-acting' Let us emphasize that chronic insomnia is best barbiturate such as phenobarbital may require treated by attacking the underlying cause, ifapparent. several hours to produce maximal effect (Sharpless, If not evident, the cause (or causes) should be care- 1965a). The reasons for the variability of pharmaco- fully sought by the physician. Lack of sleep associ- dynamic (and thus biochemical) behaviour among ated with somatic pain or with a psychiatric problem, the various hypnotic agents is beyond the scope of for example, may be treated best by prescribing this review (see Shideman, 1961; Sharpless, 1965a, b). analgesics, or tranquilizers and/or psychotherapy. * Postdoctoral Fellow, National Library of Medicine, Duration of action U.S. Department of Health Education and Welfare. Duration of effect is Requests for reprints should be addressed to Dr Miller, hypnotic largely dependent Box 96, University ofChicago Hospitals and Clinics, Chicago, on two factors, the intrinsic pharmacodynamic Illinois 60637, U.S.A. characteristics of the drug and the dosage used. Postgrad Med J: first published as 10.1136/pgmj.46.535.314 on 1 May 1970. Downloaded from Current survey 315 Both of these factors should be considered when in some persons following administration of a selecting a hypnotic agent. If a patient requires a barbiturate. However, such an effect appears to be drug with a rapid but brief hypnotic effect, perhaps a rather rare phenomenon. It is said to occur less one of the 'ultra-short acting' barbiturates, ordinarily frequently with chloral hydrate than with the barbi- used as intravenous anaesthetics, may be useful. turates. Similarly, the alleged capacity of hypnotics Bush, Berry & Hume (1966) studied oral sodium to produce delirium in patients with pain is rarely hexobarbital (Sombulex, Cyclonal), sodium metho- evident clinically. There seems to be little reason to hexital and sodiumthiopental(nooral preparationsof avoid prescribing hypnotics for patients in pain who the latter two drugs are commercially available) and also have insomnia. Of course, appropriate anal- their results indicate that thesethreedrugs maybe use- gesics should also be prescribed. ful in treatment ofpatients who have difficulty in fall- Gastric irritation is said to be a problem with ingasleep but who, once asleep, do not easily awaken. chloral hydrate but modem dosage forms (capsules, If a patient needs a hypnotic for both inducing syrup) appear to have largely eliminated this side and maintaining sleep, one of the longer acting effect. Chloral betaine (Beta-Chlor), a relative of hypnotics in an appropriate dose is indicated. In most chloral hydrate, is said to cause less gastric irrita- patients a 1-0 g dose of chloral hydrate, for example, tion but there is no objective evidence to support will provide adequate sleep but doses of 1-5 g or this claim. 2-0 g may be necessary in some patients. Hangover, or residual sedation after waking, is a The older designations of hypnotics as being problem with many of the hypnotics although in 'short-acting', 'medium-acting', 'long-acting', are some patients, e.g. certain hospitalized persons, this clinically and pharmacodynamically meaningless. effect may not be undesirable. The only hypnotics Such labels have no scientific meaning because there not having this side-effect are the 'ultra-short acting' are no valid human data to support them. No con- barbiturate hexobarbital (Sombulex, Cyclonal) and, trolled human studies have been done, showing that for most persons, the non-barbiturate compound specified doses of several hypnotics have different ethinamate (Valmid). Other barbiturates, although durations of action. Thus, commercial preparations called 'short-acting', are all known to have this side combining a 'short-acting' barbiturate with a effect. The non-barbiturates methyprylon (Noludar), copyright. 'moderately long-acting' barbiturate (as in Tuinal) ethchlorvynol (Arvynol, Serenesil, Placidyl), meth- are not pharmacologically rational. By increasing or aqualone (Quaalude, Melsed, Melsedin, Paxidorm) decreasing the dosage of such a drug as secobar- and glutethimide (Doriden), have this side-effect in bital, for instance, the physician can usually obtain some persons, also; there are no well-designed any effect from relatively brief and shallow sedation studies demonstrating their lack of hangover. With to a prolonged and rather profound coma-like state. all hypnotics hangover can be minimized by titrating each patient's insomnia against different doses of a Dose variability particular drug. http://pmj.bmj.com/ The dose required for a satisfactory hypnotic Various allergic reactions have been noted with effect varies greatly among individual patients. Such the use of all hypnotics. The symptoms usually are variability can be explained in part by individual skin rash, pruritus, nausea and vomiting. differences in the metabolism of a drug or in the More serious adverse effects have been en- response of individual central nervous systems to a countered. The Registry on Adverse Reactions of the given concentration of the drug. But the necessary American Medical Association has received a num- dose is also related to other differences in a patient's ber of reports of reactions to hypnotic drugs (see condition, such as the degree of anxiety or depres- Table 1). A direct causal relationship was not de- on September 29, 2021 by guest. Protected sion present, and to the environment in which he finitely established because these reports come from a must sleep. Thus, the use of a 'standard' dose under variety of sources not subject to follow-up investiga- all circumstances is not rational (or efficacious) tion. The reports may represent only a fraction of therapeutics. A patient should first receive a rela- the reactions which do occur. tively low dose of a hypnotic (e.g. 0-5 g of chloral In addition to the unpublished Registry reports, hydrate or 50 mg of secobarbital or pentobarbital). adverse reactions have also been reported in the If hypnosis is not achieved, the dose may be doubled literature. Two cases of peripheral neuropathy due or even tripled. It is generally better therapeutics to to glutethimide werereportedbyBartholomew (1961). adjust the dose of a specific drug with which the Cases of thrombocytopenia following the use of physician is familiar to the individual requirements ethinamate have been reported (Sharpless, 1965b). of the patient than to try other drugs. Methaqualone has been cited as a possible cause of aplastic anaemia (New Drugs, 1967). Side-effects Acute intoxication or poisoning with the hypnotics Paradoxical mental excitement reportedly occurs is common. It has been estimated that there are Postgrad
Recommended publications
  • Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution
    ® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks.
    [Show full text]
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • RUNNING HEAD: Anomalous Experiences and Hypnotic Suggestibility
    Anomalous experiences and hypnotic suggestibility 1 RUNNING HEAD: Anomalous experiences and hypnotic suggestibility Anomalous experiences are more prevalent among highly suggestible individuals who are also highly dissociative David Acunzo1, Etzel Cardeña2, & Devin B. Terhune3* 1 Centre for Mind/Brain Sciences, University of Trento, Rovereto, Italy 2 Department of Psychology, Lund University, Lund, Sweden 3 Department of Psychology, Goldsmiths, University of London, London, UK * Correspondence address: Devin B. Terhune Department of Psychology Goldsmiths, University of London 8 Lewisham Way New Cross, London, UK SE14 6NW [email protected] Word count: 3,186 The data that support the findings of this study are openly available in Open Science Framework at osf.io/cfa3r. Anomalous experiences and hypnotic suggestibility 2 Abstract Introduction: Predictive coding models propose that high hypnotic suggestibility confers a predisposition to hallucinate due to an elevated propensity to weight perceptual beliefs (priors) over sensory evidence. Multiple lines of research corroborate this prediction and demonstrate a link between hypnotic suggestibility and proneness to anomalous perceptual states. However, such effects might be moderated by dissociative tendencies, which seem to account for heterogeneity in high hypnotic suggestibility. We tested the prediction that the prevalence of anomalous experiences would be greater among highly suggestible individuals who are also highly dissociative. Methods: We compared high and low dissociative highly suggestible participants and low suggestible controls on multiple psychometric measures of anomalous experiences. Results: High dissociative highly suggestible participants reliably reported greater anomalous experiences than low dissociative highly suggestible participants and low suggestible controls, who did not significantly differ from each other. Conclusions: These results suggest a greater predisposition to experience anomalous perceptual states among high dissociative highly suggestible individuals.
    [Show full text]
  • Date Rape and Steroid Panels, Updated Feb 1 2010
    DRUG-FACILITATED SEXUAL ASSAULT (aka “DATE RAPE”) AND STEROID PANELS (Effective January 26, 2010) Basic Date Rape Panel Comprehensive Date Rape Panel • GHB (Hair Only) • Ketamine • GHB • Benzodiazepines, including Rohypnol • Benzodiazepines Alprazolam Clonazepam Alprazolam Clonazepam Diazepam Flunitrazepam (Rohypnol) Diazepam Flunitrazepam Lorazepam Oxazepam Lorazepam Oxazepam Temazepam Nitrazepam Temazepam Nitrazepam • Opioids Codeine Hydrocodone Comprehensive Date Rape Panel Meperidine Tramadol (Urine Only) Methadone Fentanyl • GHB • Sedatives/Hypnotics Ketamine Methaqualone • Barbiturates Zolpidem Zopiclone Amobarbital Butalbital Pentobarbital Phenobarbital • Over-The-Counter Drugs Secobarbital Diphenhydramine Dextromethorphan Doxylamine Chlorpheniramine • Benzodiazepines Brompheniramine Promethazine Alprazolam Clonazepam Pheniramine Diazepam Flunitrazepam Lorazepam Oxazepam • Muscle Relaxants Temazepam Nitrazepam Carisoprodol Meprobamate • Opioids Cyclobenzaprine Methocarbamol Codeine Morphine • Hallucinogens (PCP) Hydrocodone Hydromorphone Oxycodone Oxymorphone Meperidine Tramadol ANABOLIC STEROID PANEL Methadone Fentanyl (Urine or Blood) Propoxyphene Buprenorphine Androstenedione Boldenone • Sedatives/Hypnotics Fluoxymesterolone Mesterolone Ketamine Methaqualone 17-a-Methyltestosterone Methenolone Zolpidem Zopiclone Methandrostenolone Nandrolone • Over-The-Counter Drugs Norethandrolone Oxandrolone Diphenhydramine Dextromethorphan Stanozolol Trenbolone Doxylamine Chlorpheniramine Brompheniramine Promethazine Pheniramine For additional steroids, • Muscle Relaxants call for details and pricing Carisoprodol Meprobamate EXPERTOX, INC. Cyclobenzaprine Methocarbamol Blood should only be 1803 CENTER STREET, SUITE A submitted for date rape • Hallucinogens DEER PARK, TX 77536 PCP MDMA panels if within five (5) hours of 281.476.4600 MDA MDEA ingestion. FAX 281.930.8856 Cannabinoids (Carboxy-THC) • WWW.EXPERTOX.COM Turaround Time: Ten (10) Urine must be collected within five (5) days business days from specimen of drug exposure receipt at the lab .
    [Show full text]
  • Determination of Barbiturates and 11-Nor-9-Carboxy-Δ9-THC in Urine
    Determination of Barbiturates and 11-Nor-9-carboxy- 9-THC in Urine using Automated Disposable Pipette Extraction (DPX) and LC/MS/MS Fred D. Foster, Oscar G. Cabrices, John R. Stuff, Edward A. Pfannkoch GERSTEL, Inc., 701 Digital Dr. Suite J, Linthicum, MD 21090, USA William E. Brewer Department of Chemistry and Biochemistry, University of South Carolina, 631 Sumter St. Columbia, SC 29208, USA KEYWORDS DPX, LC/MS/MS, Sample Preparation, High Throughput Lab Automation ABSTRACT This work demonstrates the use of disposable pipette extraction (DPX) as a fast and automated sample preparation technique for the determination of barbiturates and 11-nor-9- carboxy- 9-THC (COOH-THC) in urine. Using a GERSTEL MultiPurpose Sampler (MPS) with DPX option coupled to an Agilent 6460 LC-MS/MS instrument, 8 barbiturates and COOH-THC were extracted and their concentrations determined. The resulting average cycle time of 7 min/ sample, including just-in-time sample preparation, enabled high throughput screening. Validation results show that the automated DPX-LC/ AppNote 1/2013 MS/MS screening method provides adequate sensitivity for all analytes and corresponding internal standards that were monitored. Lower limits of quantitation (LLOQ) were found to be 100 ng/mL for the barbiturates and 10 ng/mL for COOH-THC and % CVs were below 10 % in most cases. INTRODUCTION The continuously growing quantity of pain management sample extract for injection [1-2]. The extraction of the drugs used has increased the demand from toxicology Barbiturates and COOH-THC is based on the DPX-RP- laboratories for more reliable solutions to monitor S extraction method described in an earlier Application compliance in connection with substance abuse and/or Note detailing monitoring of 49 Pain Management diversion.
    [Show full text]
  • Definition of Controlled Substance Schedules
    UPDATED MARCH 2018 DEFINITION OF CONTROLLED SUBSTANCE SCHEDULES Drugs and other substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15. Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the U.S., their relative abuse potential, and likelihood of causing dependence when abused. Examples of the drugs in each schedule are listed below. Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4- methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. 1 Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
    [Show full text]
  • An FAQ Explaining the Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly
    Pharmacy Quality Measures An FAQ Explaining the Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly by Natalie Bari WHERE DOES THIS MEASURE sures feature medications from the the diagnoses (such as insomnia, agi- FIT INTO THE OVERALL MEDI- American Geriatrics Society’s Beers tation, delirium) that the Beers Criteria CARE PART D STAR RATINGS? Criteria for potentially inappropriate state should be avoided. This measure was endorsed by the medication use in older adults. The Pharmacy Quality Alliance (PQA) original HRM measure discussed the WHAT DOES THIS MEASURE in May 2014. But to date, it has not use of non-benzodiazepine sedative ANALYZE? been adopted by the Medicare Part D hypnotics, but it did not include This measure calculates the percent of Star Ratings program. The measure benzodiazepines as they were listed as patients 65 years of age and older who is often described as an extension “avoid only for treatment of insomnia, have received two or more prescription of the PQA measure on the use of agitation or delirium.” The additional fills for any benzodiazepine sedative high-risk medications in the elderly measure was created to address the hypnotic for a cumulative period of (HRM), which was used in the calcu- concern that an unintended conse- more than 90 days. The benzodiaze- lation of the CMS 2015 Star Ratings quence of the HRM measure would be pine sedative hypnotic medications using 2013 claims data. Both mea- increased use of benzodiazepines for are defined to include estazolam, 32 America’s PHARMACIST | January 2015 temazepam, triazolam, flurazepam, them frequently over a prolonged peri- use of the benzodiazepine agents spe- and quazepam.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • Since the Introduction of Extracorporeal Hemodialysis For
    ROBERT P. DAVIS* WILLIAM B. BLYTHE ** Department of Medicine, University of North Carolina School of Medicire, MARGARET NEWTONt Chapel Hill, North Carolina LOUIS G. WELTt THE TREATMENT OF INTOXICATION WITH ETHYNYL-CYCLOHEXYL CARBAMATE (VALMIDR) BY EXTRACORPOREAL HEMODIALYSIS: A CASE REPORT Since the introduction of extracorporeal hemodialysis for the management of renal failure, its usefulness in the treatment of otherwise fatal poisoning by various chemical agents has been repeatedly demonstrated. Among these agents have been various barbiturates,' salicylates,' and bromide.' Recent experience with a case of intoxication with ethynyl-cyclohexyl carbamate (Fig. 1), a short-acting nonbarbiturate hypnotic,' provided an opportunity to demonstrate its dialyzability. Although the poisoning proved fatal in this instance, the ability to remove an appreciable quantity of the drug by hemodialysis suggests that patients with severe intoxication coming under observation earlier may be treated by this method more successfully. CASE HISTORY M.F.K., NCMH Unit No. 05-26-69 A 24-year-old single white female graduate student was brought to the Emergency Ward of the North Carolina Memorial Hospital at 9:30 p.m. on 9/25/58. She had been found comatose in her apartment shortly before with the beginning of a "suicide note" and an empty prescription bottle discovered near her body. The prescription had been refilled one week previously after a long interval for at least thirty 0.5 gram tablets of ethynyl-cyclohexyl-carbamate (ValmidR, Lilly). The patient was last heard from specifically 26 hours prior to the discovery prompted by her having missed several specific appointments throughout the day. Past medical history, obtained from friends and previous medical record, was noncontributory.
    [Show full text]
  • Pharmacological Treatments in Insomnia
    Pharmacological treatments in insomnia Sue Wilson Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London Drugs used in insomnia Licensed for insomnia •GABA-A positive allosteric modulators •melatonin (modified release) •promethazine •diphenhydramine •doxepin (USA) Unlicensed prescribed frequently •antihistamines (and OTC) •antidepressants Sometimes prescribed drugs for psychosis Some GABA-A positive allosteric modulators Drugs acting at the GABA-A benzodiazepine receptor zopiclone zolpidem zaleplon benzodiazepines eg temazepam, lorazepam (safe in overdose, as long as no other drug involved) Drugs acting at the barbiturate/alcohol receptor chloral hydrate/chloral betaine clomethiazole (dangerous in overdose) GABA calms the brain Gamma aminobutyic acid (GABA) is the main inhibitory transmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability and its receptors are prolific throughout the brain, in cortex, limbic system, thalamus and cerebellum sedative Increase anticonvulsant GABA anxiolytic function ataxia, memory effects Effects of GABA-A positive allosteric modulators •These drugs enhance the effect of GABA, the main inhibitory neurotransmitter in the brain •They all produce sedation, sleep promotion, ataxia, muscle relaxation, effects on memory, anticonvulsant effects •Therefore for insomnia the duration of action of the drug is important – these effects are unwanted during the day Effects of these GABA-ergic drugs on sleep EEG/PSG • Appearance of
    [Show full text]
  • Intravenous Anesthetics  a Drug That Induces Reversible Anesthesia  the State of Loss of Sensations, Or Awareness
    DR.MED. ABDELKARIM ALOWEIDI AL-ABBADI ASSOCIATE PROF. FACULTY OF MEDICINE THE UNIVERSITY OF JORDAN Goals of General Anesthesia Hypnosis (unconsciousness) Amnesia Analgesia Immobility/decreased muscle tone (relaxation of skeletal muscle) Reduction of certain autonomic reflexes (gag reflex, tachycardia, vasoconstriction) Intravenous Anesthetics A drug that induces reversible anesthesia The state of loss of sensations, or awareness. Either stimulates an inhibitory neuron, or inhibits an excitatory neuron. Organs are divided according to blood perfusion: High- perfusion organs (vessel-rich); brain takes up disproportionately large amount of drug compared to less perfused areas (muscles, fat, and vessel-poor groups). After IV injection, vessel-rich group takes most of the available drug Drugs bound to plasma proteins are unavailable for uptake by an organ After highly perfused organs are saturated during initial distribution, the greater mass of the less perfused organs continue to take up drug from the bloodstream. As plasma concentration falls, some drug leaves the highly perfused organs to maintain equilibrium. This redistribution from the vessel-rich group is responsible for termination of effect of many anesthetic drugs. Compartment Model Inhibitory channels : GABA-A channels ( the main inhibitory receptor). Glycine channels. Excitatory channels : Neuronal nicotic. NMDA. Rapid onset (mainly unionized at physiological pH) High lipid solubility Rapid recovery, no accumulation during prolonged infusion Analgesic
    [Show full text]